开云app官网登录入口网页版-官方正版

#VAST#

17篇内容 | 664人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1796712, encodeId=c9061e967125b, content=<a href='/topic/show?id=e37618298aa' target=_blank style='color:#2F92EE;'>#VAST#</a>, objectTitle=Cancer Commun：贝伐珠单抗生物类似物LY01008对比贝伐珠单抗(Avastin)一线治疗中国不可切除、转移或复发的非鳞状非小细胞肺癌患者的疗效和安全性:一项多中心、随机、双盲III期试验, objectType=article, longId=213612, objectId=25b221361280, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=25b221361280, replyNumber=0, likeNumber=109, createdTime=2021-10-01, rootId=0, userName=循证小兵, userId=7a3710, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=25b221361280, moduleTitle=Cancer Commun：贝伐珠单抗生物类似物LY01008对比贝伐珠单抗(Avastin)一线治疗中国不可切除、转移或复发的非鳞状非小细胞肺癌患者的疗效和安全性:一项多中心、随机、双盲III期试验, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=25b221361280)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1796711, encodeId=28e91e9671154, content=<a href='/topic/show?id=e37618298aa' target=_blank style='color:#2F92EE;'>#VAST#</a>, objectTitle=Bio-Thera向欧洲药品管理局提交了Avastin生物仿制药BAT1706的营销授权申请（MAA）。, objectType=article, longId=203853, objectId=e1e7203853fc, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=e1e7203853fc, replyNumber=0, likeNumber=76, createdTime=2020-12-24, rootId=0, userName=循证小兵, userId=7a3710, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=e1e7203853fc, moduleTitle=Bio-Thera向欧洲药品管理局提交了Avastin生物仿制药BAT1706的营销授权申请（MAA）。, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=e1e7203853fc)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1796710, encodeId=06001e96710b4, content=<a href='/topic/show?id=e37618298aa' target=_blank style='color:#2F92EE;'>#VAST#</a>, objectTitle=PD-L1单抗Tecentriq联合VEGF单抗Avastin：在中国获准治疗常见的肝癌患者, objectType=article, longId=202660, objectId=e6f9202660eb, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=e6f9202660eb, replyNumber=0, likeNumber=79, createdTime=2020-12-13, rootId=0, userName=循证小兵, userId=7a3710, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=e6f9202660eb, moduleTitle=PD-L1单抗Tecentriq联合VEGF单抗Avastin：在中国获准治疗常见的肝癌患者, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=e6f9202660eb)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1796709, encodeId=13ed1e967093d, content=<a href='/topic/show?id=e37618298aa' target=_blank style='color:#2F92EE;'>#VAST#</a>, objectTitle=罗氏的Tecentriq/Avastin组合获得美国批准——用于无法切除或转移性肝癌的免疫疗法, objectType=article, longId=195322, objectId=25f219532272, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=25f219532272, replyNumber=0, likeNumber=64, createdTime=2020-06-18, rootId=0, userName=循证小兵, userId=7a3710, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=25f219532272, moduleTitle=罗氏的Tecentriq/Avastin组合获得美国批准——用于无法切除或转移性肝癌的免疫疗法, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=25f219532272)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1796708, encodeId=09da1e967080a, content=<a href='/topic/show?id=e37618298aa' target=_blank style='color:#2F92EE;'>#VAST#</a>, objectTitle=罗氏的PD-L1单抗Tecentriq联合Avastin在III期肝癌试验中将死亡风险降低了40％以上, objectType=article, longId=183550, objectId=84a4183550aa, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=84a4183550aa, replyNumber=0, likeNumber=105, createdTime=2020-09-16, rootId=0, userName=循证小兵, userId=7a3710, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=84a4183550aa, moduleTitle=罗氏的PD-L1单抗Tecentriq联合Avastin在III期肝癌试验中将死亡风险降低了40％以上, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=84a4183550aa)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1796706, encodeId=e9a21e967066f, content=<a href='/topic/show?id=e37618298aa' target=_blank style='color:#2F92EE;'>#VAST#</a>, objectTitle=2019 ESMO：罗氏的PD-L1单抗Tecentriq与VEGF单抗Avastin联合针对无法切除的肝细胞癌患者的Ib期研究中显示出令人鼓舞的结果, objectType=article, longId=180179, objectId=775a1801e9d4, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=775a1801e9d4, replyNumber=0, likeNumber=117, createdTime=2019-10-02, rootId=0, userName=循证小兵, userId=7a3710, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=775a1801e9d4, moduleTitle=2019 ESMO：罗氏的PD-L1单抗Tecentriq与VEGF单抗Avastin联合针对无法切除的肝细胞癌患者的Ib期研究中显示出令人鼓舞的结果, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=775a1801e9d4)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1796707, encodeId=45fb1e96707b9, content=<a href='/topic/show?id=e37618298aa' target=_blank style='color:#2F92EE;'>#VAST#</a>, objectTitle=罗氏PD-L1单抗Tecentriq联合VEGF单抗Avastin组合治疗肝癌的III期临床成功, objectType=article, longId=181787, objectId=0d52181e8763, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=0d52181e8763, replyNumber=0, likeNumber=77, createdTime=2020-08-31, rootId=0, userName=循证小兵, userId=7a3710, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=0d52181e8763, moduleTitle=罗氏PD-L1单抗Tecentriq联合VEGF单抗Avastin组合治疗肝癌的III期临床成功, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=0d52181e8763)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1796704, encodeId=a7ed1e9670436, content=<a href='/topic/show?id=e37618298aa' target=_blank style='color:#2F92EE;'>#VAST#</a>, objectTitle=罗氏向欧盟提起申请：Tecentriq与Avastin联合治疗肾细胞癌, objectType=article, longId=153843, objectId=27431538430e, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=27431538430e, replyNumber=0, likeNumber=89, createdTime=2019-10-02, rootId=0, userName=循证小兵, userId=7a3710, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=27431538430e, moduleTitle=罗氏向欧盟提起申请：Tecentriq与Avastin联合治疗肾细胞癌, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=27431538430e)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1796705, encodeId=c4311e967059f, content=<a href='/topic/show?id=e37618298aa' target=_blank style='color:#2F92EE;'>#VAST#</a>, objectTitle=辉瑞的Avastin生物仿制药——ZIRABEV在欧洲获批治疗多个转移性肿瘤, objectType=article, longId=160659, objectId=32b11606595c, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=32b11606595c, replyNumber=0, likeNumber=94, createdTime=2019-08-09, rootId=0, userName=循证小兵, userId=7a3710, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=32b11606595c, moduleTitle=辉瑞的Avastin生物仿制药——ZIRABEV在欧洲获批治疗多个转移性肿瘤, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=32b11606595c)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1796703, encodeId=b9841e9670388, content=<a href='/topic/show?id=e37618298aa' target=_blank style='color:#2F92EE;'>#VAST#</a>, objectTitle=Avastin生物仿制药获得欧盟批准, objectType=article, longId=127348, objectId=5d1c12e348d0, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=5d1c12e348d0, replyNumber=0, likeNumber=87, createdTime=2018-07-27, rootId=0, userName=循证小兵, userId=7a3710, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=5d1c12e348d0, moduleTitle=Avastin生物仿制药获得欧盟批准, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=5d1c12e348d0)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1796702, encodeId=fe001e967025f, content=<a href='/topic/show?id=e37618298aa' target=_blank style='color:#2F92EE;'>#VAST#</a>, objectTitle=里程碑！欧盟批准罗氏安维汀（Avastin）联合化疗治疗晚期宫颈癌, objectType=article, longId=49147, objectId=a38a4914ee9, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=a38a4914ee9, replyNumber=0, likeNumber=157, createdTime=2015-10-26, rootId=0, userName=循证小兵, userId=7a3710, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=a38a4914ee9, moduleTitle=里程碑！欧盟批准罗氏安维汀（Avastin）联合化疗治疗晚期宫颈癌, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=a38a4914ee9)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1796701, encodeId=777e1e9670195, content=<a href='/topic/show?id=e37618298aa' target=_blank style='color:#2F92EE;'>#VAST#</a>, objectTitle=药品也跨界：罗氏癌症药物Avastin能治疗眼疾, objectType=article, longId=47532, objectId=786c4e532b4, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=786c4e532b4, replyNumber=0, likeNumber=90, createdTime=2015-07-06, rootId=0, userName=循证小兵, userId=7a3710, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=786c4e532b4, moduleTitle=药品也跨界：罗氏癌症药物Avastin能治疗眼疾, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=786c4e532b4)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1796700, encodeId=b4271e967005e, content=<a href='/topic/show?id=e37618298aa' target=_blank style='color:#2F92EE;'>#VAST#</a>, objectTitle=罗氏Avastin再获批 **用于晚期宫颈癌的生物药物, objectType=article, longId=43043, objectId=f21c43043db, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=f21c43043db, replyNumber=0, likeNumber=93, createdTime=2015-07-30, rootId=0, userName=循证小兵, userId=7a3710, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=f21c43043db, moduleTitle=罗氏Avastin再获批 **用于晚期宫颈癌的生物药物, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=f21c43043db)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1796697, encodeId=7ca31e9669718, content=<a href='/topic/show?id=e37618298aa' target=_blank style='color:#2F92EE;'>#VAST#</a>, objectTitle=Avastin超标签用药真的可以吗？政府与药企到底谁在耍流氓？, objectType=article, longId=37547, objectId=aa3e3e547d5, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=aa3e3e547d5, replyNumber=0, likeNumber=94, createdTime=2014-11-01, rootId=0, userName=循证小兵, userId=7a3710, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=aa3e3e547d5, moduleTitle=Avastin超标签用药真的可以吗？政府与药企到底谁在耍流氓？, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=aa3e3e547d5)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1796699, encodeId=763c1e96699d7, content=<a href='/topic/show?id=e37618298aa' target=_blank style='color:#2F92EE;'>#VAST#</a>, objectTitle=FDA批准罗氏安维汀（Avastin）联合化疗治疗晚期宫颈癌, objectType=article, longId=39215, objectId=fcdb3921526, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=fcdb3921526, replyNumber=0, likeNumber=88, createdTime=2015-03-05, rootId=0, userName=循证小兵, userId=7a3710, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=fcdb3921526, moduleTitle=FDA批准罗氏安维汀（Avastin）联合化疗治疗晚期宫颈癌, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=fcdb3921526)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1796698, encodeId=b5591e9669841, content=<a href='/topic/show?id=e37618298aa' target=_blank style='color:#2F92EE;'>#VAST#</a>, objectTitle=欧盟批准罗氏安维汀（Avastin）用于铂耐药复发性卵巢癌, objectType=article, longId=38832, objectId=1f85388327a, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=1f85388327a, replyNumber=0, likeNumber=95, createdTime=2015-01-12, rootId=0, userName=循证小兵, userId=7a3710, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=1f85388327a, moduleTitle=欧盟批准罗氏安维汀（Avastin）用于铂耐药复发性卵巢癌, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=1f85388327a)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1796696, encodeId=ab9f1e9669643, content=<a href='/topic/show?id=e37618298aa' target=_blank style='color:#2F92EE;'>#VAST#</a>, objectTitle=NCCN PK FDA：Avastin治疗乳腺癌的存废之争, objectType=article, longId=2967, objectId=3dce296edd, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=3dce296edd, replyNumber=0, likeNumber=75, createdTime=2011-12-31, rootId=0, userName=循证小兵, userId=7a3710, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=3dce296edd, moduleTitle=NCCN PK FDA：Avastin治疗乳腺癌的存废之争, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=3dce296edd)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 风湿免疫小助手

VAST

2020-05-29

循证小兵 (审核中...)

前往app查看评论内容

#VAST#

Cancer Commun：贝伐珠单抗生物类似物LY01008对比贝伐珠单抗(Avastin)一线治疗中国不可切除、转移或复发的非鳞状非小细胞肺癌患者的疗效和安全性:一项多中心、随机、双盲III期试验

2021-10-01

循证小兵 (审核中...)

前往app查看评论内容

#VAST#

Bio-Thera向欧洲药品管理局提交了Avastin生物仿制药BAT1706的营销授权申请（MAA）。

2020-12-24

循证小兵 (审核中...)

前往app查看评论内容

#VAST#

PD-L1单抗Tecentriq联合VEGF单抗Avastin：在中国获准治疗常见的肝癌患者

2020-12-13

循证小兵 (审核中...)

前往app查看评论内容

#VAST#

罗氏的Tecentriq/Avastin组合获得美国批准——用于无法切除或转移性肝癌的免疫疗法

2020-06-18

循证小兵 (审核中...)

前往app查看评论内容

#VAST#

罗氏的PD-L1单抗Tecentriq联合Avastin在III期肝癌试验中将死亡风险降低了40％以上

2020-09-16

循证小兵 (审核中...)

前往app查看评论内容

#VAST#

2019 ESMO：罗氏的PD-L1单抗Tecentriq与VEGF单抗Avastin联合针对无法切除的肝细胞癌患者的Ib期研究中显示出令人鼓舞的结果

2019-10-02

循证小兵 (审核中...)

前往app查看评论内容

#VAST#

罗氏PD-L1单抗Tecentriq联合VEGF单抗Avastin组合治疗肝癌的III期临床成功

2020-08-31

循证小兵 (审核中...)

前往app查看评论内容

#VAST#

罗氏向欧盟提起申请：Tecentriq与Avastin联合治疗肾细胞癌

2019-10-02

循证小兵 (审核中...)

前往app查看评论内容

#VAST#

辉瑞的Avastin生物仿制药——ZIRABEV在欧洲获批治疗多个转移性肿瘤

2019-08-09

循证小兵 (审核中...)

前往app查看评论内容

#VAST#

Avastin生物仿制药获得欧盟批准

2018-07-27

循证小兵 (审核中...)

前往app查看评论内容

#VAST#

里程碑！欧盟批准罗氏安维汀（Avastin）联合化疗治疗晚期宫颈癌

2015-10-26

循证小兵 (审核中...)

前往app查看评论内容

#VAST#

药品也跨界：罗氏癌症药物Avastin能治疗眼疾

2015-07-06

循证小兵 (审核中...)

前往app查看评论内容

#VAST#

罗氏Avastin再获批 **用于晚期宫颈癌的生物药物

2015-07-30

循证小兵 (审核中...)

前往app查看评论内容

#VAST#

Avastin超标签用药真的可以吗？政府与药企到底谁在耍流氓？

2014-11-01

循证小兵 (审核中...)

前往app查看评论内容

#VAST#

FDA批准罗氏安维汀（Avastin）联合化疗治疗晚期宫颈癌

2015-03-05

循证小兵 (审核中...)

前往app查看评论内容

#VAST#

欧盟批准罗氏安维汀（Avastin）用于铂耐药复发性卵巢癌

2015-01-12

循证小兵 (审核中...)

前往app查看评论内容

#VAST#

NCCN PK FDA：Avastin治疗乳腺癌的存废之争

2011-12-31

科室
- - 订阅+
  - 更多科室
工具
服务